Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

G Järnerot; M Ström; A Danielsson; A Kilander; L Lööf; R Hultcrantz; R Löfberg; C Florén; A Nilsson; O Broström

doi:10.1046/j.1365-2036.2000.00821.x

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

G Järnerot, M Ström, A Danielsson, A Kilander, L Lööf, R Hultcrantz, R Löfberg, C Florén, A Nilsson, O Broström

Skåne University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).

METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.

RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.

CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.

Original language	English
Pages (from-to)	1159-62
Number of pages	4
Journal	Alimentary pharmacology & therapeutics
Volume	14
Issue number	9
DOIs	https://doi.org/10.1046/j.1365-2036.2000.00821.x
Publication status	Published - 2000 Sept
Externally published	Yes

Subject classification (UKÄ)

Gastroenterology and Hepatology

Free keywords

Adult
Aged
Allopurinol/administration & dosage
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
Antimetabolites/administration & dosage
Colitis, Ulcerative/drug therapy
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Mesalamine/administration & dosage
Middle Aged
Recurrence
Sweden

Access to Document

10.1046/j.1365-2036.2000.00821.x

Cite this

@article{df5bd62836cf445eb8e08da03923808e,

title = "Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis",

abstract = "BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.",

keywords = "Adult, Aged, Allopurinol/administration & dosage, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Antimetabolites/administration & dosage, Colitis, Ulcerative/drug therapy, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Mesalamine/administration & dosage, Middle Aged, Recurrence, Sweden",

author = "G J{\"a}rnerot and M Str{\"o}m and A Danielsson and A Kilander and L L{\"o}{\"o}f and R Hultcrantz and R L{\"o}fberg and C Flor{\'e}n and A Nilsson and O Brostr{\"o}m",

year = "2000",

month = sep,

doi = "10.1046/j.1365-2036.2000.00821.x",

language = "English",

volume = "14",

pages = "1159--62",

journal = "Alimentary pharmacology & therapeutics",

issn = "0269-2813",

publisher = "John Wiley & Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

AU - Järnerot, G

AU - Ström, M

AU - Danielsson, A

AU - Kilander, A

AU - Lööf, L

AU - Hultcrantz, R

AU - Löfberg, R

AU - Florén, C

AU - Nilsson, A

AU - Broström, O

PY - 2000/9

Y1 - 2000/9

N2 - BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.

AB - BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.

KW - Adult

KW - Aged

KW - Allopurinol/administration & dosage

KW - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage

KW - Antimetabolites/administration & dosage

KW - Colitis, Ulcerative/drug therapy

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Male

KW - Mesalamine/administration & dosage

KW - Middle Aged

KW - Recurrence

KW - Sweden

U2 - 10.1046/j.1365-2036.2000.00821.x

DO - 10.1046/j.1365-2036.2000.00821.x

M3 - Article

C2 - 10971232

SN - 0269-2813

VL - 14

SP - 1159

EP - 1162

JO - Alimentary pharmacology & therapeutics

JF - Alimentary pharmacology & therapeutics

IS - 9

ER -

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

Abstract

Subject classification (UKÄ)

Free keywords

Access to Document

Fingerprint

Cite this